PT - JOURNAL ARTICLE AU - Kislaya, Irina AU - Casaca, Pedro AU - Borges, Vítor AU - Sousa, Carlos AU - Ferreira, Bibiana I. AU - Fernandes, Eugénia AU - Dias, Carlos Matias AU - Duarte, Sílvia AU - Almeida, José Pedro AU - Grenho, Inês AU - Coelho, Luís AU - Ferreira, Rita AU - Ferreira, Patrícia Pita AU - Isidro, Joana AU - Pinto, Miguel AU - Menezes, Luís AU - Sobral, Daniel AU - Nunes, Alexandra AU - Santos, Daniela AU - Gonçalves, António Maia AU - Vieira, Luís AU - Gomes, João Paulo AU - Leite, Pedro Pinto AU - Nunes, Baltazar AU - Machado, Ausenda AU - Peralta-Santos, André TI - SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal AID - 10.1101/2022.07.25.22277996 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.25.22277996 4099 - http://medrxiv.org/content/early/2022/07/25/2022.07.25.22277996.short 4100 - http://medrxiv.org/content/early/2022/07/25/2022.07.25.22277996.full AB - Background In a context of multiple Omicron lineages circulation, it is relevant to clarify the effect of vaccination and previous infections on the risk of infection and severe post-infection outcomes.Methods Using electronic health records and SARS-CoV-2 laboratory surveillance data, we conducted a case-case and a cohort study covering the period of Omicron BA.2/BA.5 lineage replacement in Portugal, to compare vaccine effectiveness of complete primary and booster dose against infection, COVID-19 hospitalization, and mortality. Variant classification was performed through whole-genome sequencing (WGS) or Spike Gene Target Failure (SGTF).Findings Between April 25 and June 10, 2022, within a total of 27702 collected samples, 55.5% were classified as BA.2 and the remaining as BA.5. We observed no evidence of reduced vaccine effectiveness for the primary complete vaccination (OR=1.07, CI95%:0.93-1.23) or booster dose vaccination (OR=0.96, CI95%:0.84-1.09) against BA.5 infection compared with BA.2. The protection against reinfection was inferior in BA.5 cases when compared with BA.2 (OR=1.44; CI95%:1.30-1.60). Among those infected with BA.5, booster vaccination was associated with 77% and 88% of reduction in risk of COVID-19 hospitalization and death, respectively, while higher risk reduction was found for BA.2 cases, with 93% and 94%, respectively.Interpretation This study shows that the SARS-CoV-2 Omicron BA.5 lineage is associated with higher odds of reinfection compared with Omicron BA.2, regardless of the vaccination status.Although less effective compared with BA.2, COVID-19 booster vaccination still offers substantial protection against severe outcomes following BA.5 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe acquisition of sequencing equipment/reagents used in this study by INSA was partially funded by the HERA project (Grant/2021/PHF/23776) supported by the European Commission through the European Centre for Disease Control, and also partially funded by the GenomePT project (POCI-01-0145-FEDER-022184), supported by COMPETE 2020 Operational Programme for Competitiveness and Internationalisation (POCI), Lisboa Portugal Regional Operational Programme (Lisboa2020), Algarve Portugal Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), and by the Portuguese Science and Technology Foundation (FCT).” ABC laboratory received public funding through the Project ALG-D2-2021-06 VISITOR (VarIants Screen In souThern pORtugal) Monitoring Variants of Concern (VOC) in Southern Portugal and the Portuguese Science and Technology Foundation national support through CHRC (UIDP/04923/2020) The funders had no role in study design, data collection, data analysis, interpretation of the data, writing of the report, or decision to submit the paper for publication. The findings, opinions and conclusions described in this article reflect the views of the authors only.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Statement The genomic surveillance of SARS-CoV-2 in Portugal is regulated by the Assistant Secretary of State and Health Executive Order (Despacho n. 331/2021 of January 11, 2021). The study protocol received the clearance of the Ethics Committee of Instituto Nacional de Saude Dr Ricardo Jorge on June 15, 2022. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the present study can be available upon reasonable request from the data owner